An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations

Drug Metabolism and Disposition

Volumn 40, Issue 11, 2012, Pages 2162-2173

  Doran, Angela C ^a   Osgood, Sarah M ^a   Mancuso, Jessica Y ^a   Shaffer, Christopher L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 CHLORO 5 FLUORO 2 (3 METHOXY 2 METHYLPHENOXY)BENZYL]METHYLAMINE; CARBAMAZEPINE; CE 157119; CITALOPRAM; GANCICLOVIR; METHYLAMINE; METOCLOPRAMIDE; N [3 [4 (5 CYANO 2 THIENYL)PHENYL]TETRAHYDRO 2H PYRAN 4 YL]PROPANE 2 SULFONAMIDE; NORCLOZAPINE; PALIPERIDONE; PF 4778574; QUINIDINE; RISPERIDONE; SULFONAMIDE; THIOPENTAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; MALE; MAXIMUM PLASMA CONCENTRATION; METHODOLOGY; MOLECULAR WEIGHT; NEUROPHARMACOKINETICS; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUBARACHNOID SPACE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; DOGS; ISOXAZOLES; MALE; P-GLYCOPROTEIN; PRIMATES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; THIOPHENES;

EID: 84867669201     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046391     Document Type: Article

References (42)

1. Becker S and Liu X (2006) Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos 34:855-861.
2. Bihorel S, Camenisch G, Gross G, Lemaire M, and Scherrmann JM (2006) Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. Drug Metab Dispos 34:1945-1949. (Pubitemid 44837753)
3. Boström E, Simonsson US, and Hammarlund-Udenaes M (2006) In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/ pharmacodynamics. Drug Metab Dispos 34:1624-1631. (Pubitemid 44285405)
4. Brown EA, Griffiths R, Harvey CA, and Owen DA (1986) Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system. Br J Pharmacol 87:569-578. (Pubitemid 17178775)
5. Claffey MM, Fliri AFJ, Gallaschun RJ, and O'Donnell CJ (2006) inventors; Pfizer Products, Inc., assignee. Therapeutic diphenyl ether ligands. World patent WO2006027684A1. 2006 Mar 16.
6. de Lange EC and Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41:691-703.
7. de Roos AM, Rekker RF, and Nauta WT (1970) The base strength of substituted 2-(diphenyl-methoxy)- N,N-dimethylamines. Arzneim Forsch 20:1763-1765.
8. Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, and Liston TE (2011) Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos 39:1270-1277.
9. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165-174. (Pubitemid 40023528)
10. Estep KG, Fliri AFJ, and O'Donnell CJ (2008); Pfizer, Inc., assignee. Sulfonamides and pharmaceutical compositions thereof. World patent WO2008120093A1. 26 Mar 2008.
11. Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, and Bredberg U (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353-362.
12. Fridén M, Gupta A, Antonsson M, Bredberg U, and Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711-1719. (Pubitemid 47296068)
13. Fridén M, Ljungqvist H, Middleton B, Bredberg U, and Hammarlund-Udenaes M (2010) Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metabol 30:150-161.
14. Hammarlund-Udenaes M (2010) Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 106:215-220.
15. Hammarlund-Udenaes M, Fridén M, Syvänen S, and Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25:1737-1750.
16. Hitchcock SA and Pennington LD (2006) Structure-brain exposure relationships. J Med Chem 49:7559-7583. (Pubitemid 46033646)
17. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
18. Ito K, Uchida Y, Ohtsuki S, Aizawa S, Kawakami H, Katsukura Y, Kamiie J, and Terasaki T (2011) Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 100:3939-3950.
19. Kaddoumi A, Choi SU, Kinman L, Whittington D, Tsai CC, Ho RJ, Anderson BD, and Unadkat JD (2007) Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab Dispos 35:1459-1462. (Pubitemid 47296072)
20. Kalvass JC and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338. (Pubitemid 36124162)
21. Kalvass JC, Olson ER, Cassidy MP, Selley DE, and Pollack GM (2007) Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein- competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 323:346-355. (Pubitemid 47443282)
22. Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, and Sugiyama Y (2011) Quantitative evaluation of the impact of active efflux by P-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther 339:935-944.
23. Kola I and Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715. (Pubitemid 39173511)
24. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, and Monshouwer M (2009a) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787-793.
25. Liu X, Vilenski O, Kwan J, Apparsundaram S, and Weikert R (2009b) Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos 37:1548-1556.
26. Mukherjee J, Christian BT, Narayanan TK, Shi B, and Mantil J (2001) Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 25:476-488. (Pubitemid 32830952)
27. Neuwelt EA, Bauer B, Fahlke C, Fricker G, Iadecola C, Janigro D, Leybaert L, Molnár Z, O'Donnell ME, Povlishock JT, et al. (2011) Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 12:169-182.
28. Pangalos MN, Schechter LE, and Hurko O (2007) Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6:521-532. (Pubitemid 47019441)
29. Roberts BM, Holden DE, Shaffer CL, Seymour PA, Menniti FS, Schmidt CJ, Williams GV, and Castner SA (2010) Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction. Behav Brain Res 212:41-48.
30. Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, Jansson B, Björkman S, Terasaki T, and Hammarlund-Udenaes M (2011) Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. J Pharm Sci 100:3912-3923.
31. Schoepp DD (2011) Where will new neuroscience therapies come from? Nat Rev Drug Discov 10:715-716.
32. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, and Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73. (Pubitemid 26112775)
33. Shaffer CL (2008) Determining cross-species exposure-receptor occupancy relationships for a dual-pharmacology CNS compound: an exercise in translational medicine. Fifteenth North American Regional ISSX Meeting; 2008 Oct 12-16; San Diego, CA. International Society for the Study of Xenobiotics, Washington, DC.
34. Shaffer CL (2010) Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-species pharmacologic exposure-response relationships. Annu Rep Med Chem 45:55-70.
35. Shen DD, Artru AA, and Adkison KK (2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56:1825-1857. (Pubitemid 39307054)
36. Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ,et al. (2008) Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518-1535.
37. Summerfield SG, Stevens AJ, Cutler L, del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, and Jeffrey P (2006) Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282-1290. (Pubitemid 43345304)
38. Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Långström B, Knudsen GM, and Hammarlund-Udenaes M (2009) Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37:635-643.
39. Tien JH (1991) Transdermal-controlled administration of oxycodone. J Pharm Sci 80:741-743.
40. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, and Terasaki T (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 117:333-345.
41. Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, and Read KD (2009) Receptor occupancy and brain free fraction. Drug Metab Dispos 37:753-760.
42. Westlake WJ (1988) Bioavailability and bioequivalence of pharmaceutical formulations, in Biopharmaceutical Statistics for Drug Development (Peace KE ed) pp 329-352, Marcel Dekker, Inc., New York.